ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • CNS Vasculitis
  • CNS Vasculitis and spine involvement
  • CNS Vasculitis and treatment
  • Co-morbidities
  • Co-morbidities and ankylosing spondylitis (AS)
  • Co-morbidities and crystal-induced arthritis
  • Co-morbidities and epidemiologic methods
  • Co-morbidities and psoriatic arthritis
  • Co-morbidities and rheumatoid arthritis (RA)
  • Co-morbidities and systemic lupus erythematosus (SLE)
  • co-stimulation
  • co-stimulation and mouse model
  • co-stimulation and rheumatoid arthritis (RA)
  • co-stimulation and salivary gland
  • co-stimulation and therapeutic targeting
  • coagulation
  • coagulation disorder
  • coagulation disorder and juvenile SLE
  • coagulation disorder and thrombosis
  • cocaine
  • coccidioidomycosis
  • Cogalt1
  • cognitive behavioral therapy
  • cognitive behavioral therapy and prevention
  • Cognitive dysfunction
  • cognitive dysfunction and angiotensin
  • cognitive dysfunction and clinical research
  • cognitive dysfunction and depression
  • Cognitive dysfunction and fibromyalgia
  • cognitive dysfunction and Lupus
  • cognitive dysfunction and measure
  • Cognitive dysfunction and osteoarthritis
  • cognitive dysfunction and quality of life
  • Cognitive dysfunction and rheumatoid arthritis (RA)
  • cognitive dysfunction and risk assessment
  • cognitive dysfunction and stress
  • Cognitive dysfunction and systemic lupus erythematosus (SLE)
  • Cognitive dysfunction and uric acid
  • Cohort Study
  • Colchicine
  • colchicine and familial Mediterranean fever
  • colchicine and gout
  • colchicine and price
  • Collagen
  • collagen and anti-TNF therapy
  • collagen and fibroblasts
  • collagen and fibrosis
  • collagen and histone acetylation
  • collagen and human leukocyte antigens (HLA)
  • collagen and inflammatory arthritis
  • collagen and interleukins (IL)
  • collagen and osteoarthritis
  • collagen and rheumatoid arthritis (RA)
  • collagen and scleroderma
  • collagen and systemic sclerosis
  • collagen and tolerance
  • collagen and treatment
  • Collagen-Induced Arthritis
  • column and hedgehog
  • combination therapies
  • combination therapies and comparative effectiveness and harms
  • combination therapies and LFN
  • combination therapies and methotrexate (MTX)
  • combination therapies and remission
  • combination therapies and rheumatoid arthritis
  • combination therapies and rheumatoid arthritis (RA)
  • combination treatment
  • Communication
  • communication and positive affect
  • communication and quality of care
  • communication and self-management
  • communications
  • Community programs
  • community programs and exercise
  • community programs and legislation
  • community programs and nursing roles
  • Community programs and systemic lupus erythematosus (SLE)
  • Comon Data Elements
  • Comorbidity
  • comorbidity and administrative databases
  • comorbidity and cluster
  • comorbidity and disability
  • comorbidity and drug treatment
  • comorbidity and epidemiologic methods
  • comorbidity and fatigue
  • Comorbidity and fibromyalgia
  • comorbidity and giant cell arteritis
  • Comorbidity and gout
  • comorbidity and hypertension
  • comorbidity and incident
  • Comorbidity and juvenile idiopathic arthritis (JIA)
  • comorbidity and magnetic resonance imaging (MRI)
  • comorbidity and malignancy
  • comorbidity and osteoarthritis
  • comorbidity and physical activity
  • Comorbidity and psoriatic arthritis
  • comorbidity and qualitative
  • comorbidity and questionnaires
  • comorbidity and renal disease
  • comorbidity and rheumatic disease
  • Comorbidity and rheumatoid arthritis (RA)
  • Comorbidity and spondylarthritis
  • Comorbidity and spondylarthropathy
  • comorbidity and systemic lupus erythematosus (SLE)
  • Comorbidity and vasculitis
  • comparative effectiveness
  • Comparative effectiveness and harms
  • comparative effectiveness and harms and epidemiologic methods
  • comparative effectiveness and harms and juvenile idiopathic arthritis (JIA)
  • comparative effectiveness and harms and patient outcomes
  • comparative effectiveness and harms and pediatric rheumatology
  • comparative effectiveness and harms and psoriatic arthritis
  • comparative effectiveness and harms and rheumatoid arthritis
  • comparative effectiveness and harms and rheumatoid arthritis (RA)
  • comparative effectiveness and harms and spondylarthritis
  • comparative effectiveness and harms and treatment
  • competency
  • competency and ultrasound
  • complement
  • complement and anakinra
  • complement and biomarkers
  • complement and complement inhibitors
  • complement and cryoglobulinemia
  • complement and flow cytometry
  • complement and genetic disorders
  • complement and immunosuppressants
  • complement and inflammation
  • complement and innate immunity
  • complement and interferons
  • complement and longitudinal studies
  • complement and nephritis
  • complement and neutrophils
  • complement and polymorphism
  • complement and pregnancy
  • complement and psoriatic arthritis
  • complement and renal disease
  • complement and rheumatoid arthritis (RA)
  • complement and scleroderma
  • complement and systemic lupus erythematosus (SLE)
  • complement and thrombosis
  • complement and vasculitis
  • complement deficiency
  • complement deficiency and genetics
  • Complement deficiency and juvenile dermatomyositis
  • complement deficiency and lupus nephritis
  • complement deficiency and systemic lupus erythematosus (SLE)
  • complement deficiency and systemic sclerosis
  • complement inhibitors
  • complement inhibitors and Immunotherapy
  • complement inhibitors and safety
  • complementary
  • Complementary alternative medicine
  • complementary alternative medicine and patient preferences
  • Complementary alternative medicine and systemic lupus erythematosus (SLE)
  • complex regional pain syndrome
  • Complex regional pain syndrome and disability
  • Compliance
  • Compliance and Disease Activity
  • Compliance and DMARDs
  • Compliance and gout
  • Compliance and Health Assessment Questionnaire
  • Compliance and laboratory tests
  • Compliance and methotrexate (MTX)
  • Compliance and qualitative
  • Compliance and rheumatoid arthritis (RA)
  • complications
  • Complications and epidemiologic methods
  • complications and genetic architecture
  • complications and morbidity and mortality
  • complications and musculoskeletal disorders
  • complications and outcomes
  • complications and rheumatoid arthritis (RA)
  • complications and rituximab
  • Complications and takayasu arteritis
  • complimentary and alternative therapy
  • Complimentary and alternative therapy and fibromyalgia
  • complimentary and alternative therapy and osteoarthritis
  • Complimentary and alternative therapy and rheumatoid arthritis (RA)
  • complimentary and diagnosis
  • computational and Drug Repositioning
  • computational phenotyping
  • Computed tomography (CT)
  • computed tomography (CT) and atherosclerosis
  • computed tomography (CT) and autologous transplantation
  • computed tomography (CT) and cardiovascular disease
  • computed tomography (CT) and coronary artery disease
  • computed tomography (CT) and cross-sectional studies
  • computed tomography (CT) and enthesopathy
  • computed tomography (CT) and gout
  • computed tomography (CT) and imaging techniques
  • computed tomography (CT) and inflammatory bowel disease (IBD)
  • computed tomography (CT) and inflammatory myositis
  • computed tomography (CT) and interstitial lung disease
  • computed tomography (CT) and juvenile idiopathic arthritis (JIA)
  • computed tomography (CT) and Knee
  • computed tomography (CT) and magnetic resonance imaging (MRI)
  • computed tomography (CT) and osteoarthritis
  • Computed tomography (CT) and osteoporosis
  • computed tomography (CT) and outcome measures
  • computed tomography (CT) and radiography
  • First |
  • « Previous Page
  • 9
  • 10
  • 11
  • 12
  • 13
  • [14]
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology